E3 PreliminaryPreliminaryPEM unclearMechanisticPeer-reviewedMachine draft
Increased sensitivity to glucocorticoids in peripheral blood mononuclear cells of chronic fatigue syndrome patients, without evidence for altered density or affinity of glucocorticoid receptors.
Visser, J, Lentjes, E, Haspels, I et al. · Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2001 · DOI
Quick Summary
Researchers found that immune cells from ME/CFS patients react more strongly to a stress hormone called dexamethasone (a type of glucocorticoid) than cells from healthy people. However, the cells have the same number of receptors for this hormone and bind it with the same strength, suggesting the heightened sensitivity comes from something happening inside the cells after the hormone attaches, rather than from problems with the receptors themselves.
Why It Matters
This finding suggests that ME/CFS patients' cells may be hypersensitive to stress hormones through mechanisms beyond receptor availability or binding—possibly involving intracellular signaling pathways. Understanding these downstream mechanisms could lead to targeted therapies and may explain some HPA axis abnormalities observed in ME/CFS.
Observed Findings
- PBMC from CFS patients and controls had identical GR binding affinity (Kd: 12.9 vs 18.8 nmol) and receptor density (4,839 vs 4,906 receptors/cell).
- GR messenger RNA expression did not differ between patients and controls.
- At low dexamethasone concentration (0.01 µmol), CFS patient cells showed 37% proliferation suppression versus 17% in controls (p<0.01).
- When cells were stimulated with phorbol 12-myristate 13-acetate, glucocorticoid sensitivity differences between groups persisted for IL-2 and TNF-alpha production but not for IL-10 and IFN-gamma.
Inferred Conclusions
- ME/CFS patients' PBMC display enhanced glucocorticoid sensitivity despite normal receptor structure and expression.
- The heightened sensitivity must arise from molecular mechanisms downstream of ligand-receptor binding rather than from altered receptor availability or affinity.
- Post-receptor signaling pathways may be dysregulated in ME/CFS immune cells.
Remaining Questions
- Which specific intracellular signaling cascades mediate the enhanced glucocorticoid responsiveness in CFS PBMC?
- Does this hypersensitivity occur in other immune cell types, and does it contribute to the clinical symptoms of ME/CFS?
- Are there differences in glucocorticoid receptor phosphorylation, translocation, or interaction with co-regulatory proteins between patients and controls?
What This Study Does Not Prove
This study does not prove that glucocorticoid hypersensitivity causes ME/CFS symptoms or is the primary driver of immune dysfunction in the disease. It also does not identify which specific intracellular pathways cause the heightened sensitivity, and findings in cultured cells may not fully reflect in vivo immune responses. The small sample size limits generalizability.
Tags
Symptom:Fatigue
Biomarker:CytokinesGene ExpressionBlood Biomarker
Method Flag:Small SampleExploratory Only
Metadata
- DOI
- 10.2310/6650.2001.34047
- PMID
- 11288761
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →